PILRA Antibodies Block Receptor Binding to Activate Myeloid Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies fail to effectively modulate the inhibitory receptor PILRA, which is associated with reduced risk of Alzheimer's disease, limiting the ability to activate myeloid cells and treat associated diseases.

Innovation Solution

Development of antibodies and antigen-binding fragments that specifically bind to human PILRA, blocking its binding to ligands and downregulating cell surface PILRA, thereby activating myeloid cells and treating diseases like cancer and neurodegenerative disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used, then treatment is simple and safe, but they fail to effectively modulate PILRA and activate myeloid cells

Engineering Contradiction:

Improveeffectiveness of PILRA modulationVSAvoidcomplexity of therapy

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs antibodies with specifically engineered affinity parameters for PILRA binding. The antibodies are designed to bind PILRA with optimized binding strength and specificity, changing the interaction parameters between the therapy and target receptor to achieve effective PILRA modulation and myeloid cell activation while maintaining safety

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces antibodies as intermediary molecules that mediate the interaction between the therapeutic agent and PILRA. These antibodies serve as mediators that specifically bind to PILRA on myeloid cells, blocking inhibitory signaling and activating immune responses without requiring direct complex therapeutic interventions

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If PILRA binding is blocked to activate myeloid cells, then anti-tumor immunity is enhanced, but off-target effects may occur

Engineering Contradiction:

Improvespecificity of PILRA bindingVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent designs antibodies with localized binding specificity targeting particular epitopes on PILRA. The antibodies exhibit local quality in their binding properties, recognizing specific regions of the PILRA receptor while ignoring other similar structures, thereby activating myeloid cells through PILRA modulation without causing off-target effects on other receptors or cells

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent replaces non-specific immunomodulatory mechanisms with highly specific antibody-PILRA interactions. Instead of using broad-acting therapies that may cause off-target effects, the invention uses engineered antibodies that specifically recognize and bind PILRA, substituting mechanical or chemical non-specific interactions with precise molecular recognition

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20230220074A1Pilra antibodies and methods of use thereof

Publication Date: 2023.07.13 ALECTOR LLC

AI summary

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.